ReviewVirchows Archiv : an international journal of pathology2017
HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature.
Review in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- HOXB13 in cancer development: molecular mechanisms and clinical implications.Frontiers of medicine · 2025Review
- Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Review
- Clonal divergence and genomic meltdown in prostatic pleomorphic giant cell adenocarcinoma.Frontiers in immunology · 2025Article
- Unusual Type of Acinar Adenocarcinoma of the Prostate With Low PSA: A Histopathological Report of Two Cases of Pleomorphic Giant Cell Adenocarcinoma.Case reports in oncological medicine · 2025Article
- Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes.Virchows Archiv : an international journal of pathology · 2023Article
- Paralogous HOX13 Genes in Human Cancers.Cancers · 2019Review
- DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.Histopathology · 2019Article
- Portrait of Tissue-Specific Coexpression Networks of Noncoding RNAs (miRNA and lncRNA) and mRNAs in Normal Tissues.Computational and mathematical methods in medicine · 2019Article
- HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder.Virchows Archiv : an international journal of pathology · 2018Article
- Letter to the editor: reply to Valeria Barresi "HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder".Virchows Archiv : an international journal of pathology · 2018Article
- Pleomorphic giant cell carcinoma of the prostate: A case report and mini‑review of the literature.Medicine internationalArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of an 81-year-old patient with a pleomorphic giant cell adenocarcinoma of the prostate. After diagnosis, he rapidly developed bone metastasis and died within 1 year. This variant of acinar adenocarcinoma is extremely rare and prognosis is poor. This entity has been included into the 2016 WHO classification. The principal differential diagnosis is urothelial carcinoma. To assess the prostatic origin, routine immunohistochemistry can be problematic. Loss of epitopes in this poorly differentiated entity can occur, such as loss of expression of PSA and p504s. We recently described a very sensitive and specific marker of prostate cancer, HOXB13, which once again has proven to be highly specific and sensitive. This is the first description of a pleomorphic giant cell prostate cancer expressing HOXB13.
Indexed as
Identifiers
28484843What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.